AbCellera Biologics (ABCL) stock surged over 15% on Tuesday, likely in reaction to the FDA approval of two cancer regimens for Jazz Pharmaceuticals (JAZZ), with whom AbCellera has a significant collaboration. This approval indirectly benefits AbCellera due to their existing partnership for developing next-generation antibodies, which includes substantial potential milestone payments.
AbCellera Biologics (ABCL) experienced a significant stock surge, despite no direct company-specific news. The market is attributing this to the FDA's approval of two cancer treatments for Jazz Pharmaceuticals (JAZZ), a company with whom AbCellera has a substantial collaboration. This partnership, announced in June, involves upfront payments and potential milestone payments totaling up to $792 million for AbCellera, tied to the development of T-cell-engaging multispecific antibodies. The FDA approval for Jazz's products strengthens their oncology portfolio, which in turn increases the likelihood of AbCellera realizing those milestone payments. This event is a positive catalyst for ABCL in the short term, as it validates their partnership and potential future revenue streams, while for JAZZ, it represents a direct expansion of their market offerings. The key opportunity for traders is the potential for continued upside in ABCL as the market fully prices in the implications of this strengthened partnership.